Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) FCF Margin: 2020-2022

Historic FCF Margin for Immuneering (IMRX) over the last 2 years, with Dec 2022 value amounting to -2,597,344.18%.

  • Immuneering's FCF Margin fell 259246418.00% to -2,597,344.18% in Q4 2022 from the same period last year, while for Dec 2022 it was -14,148.44%, marking a year-over-year decrease of 1266227.00%. This contributed to the annual value of -14,148.44% for FY2022, which is 1266227.00% down from last year.
  • Immuneering's FCF Margin amounted to -2,597,344.18% in Q4 2022, which was down 8,949.64% from -28,701.08% recorded in Q3 2022.
  • Immuneering's FCF Margin's 5-year high stood at -511.54% during Q3 2020, with a 5-year trough of -2,597,344.18% in Q4 2022.
  • Over the past 3 years, Immuneering's median FCF Margin value was -3,378.13% (recorded in 2021), while the average stood at -265,287.05%.
  • Data for Immuneering's FCF Margin shows a maximum YoY crashed of 259,246,418bps (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Immuneering's FCF Margin stood at -825.64% in 2020, then tumbled by 405,436bps to -4,880.00% in 2021, then crashed by 259,246,418bps to -2,597,344.18% in 2022.
  • Its FCF Margin was -2,597,344.18% in Q4 2022, compared to -28,701.08% in Q3 2022 and -10,182.56% in Q2 2022.